[
  {
    "ts": null,
    "headline": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
    "summary": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
    "url": "https://finnhub.io/api/news?id=b0d5315e4d5c12507ecf204667f73122509f5d6223198730d54f50c14f946dc2",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738339270,
      "headline": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
      "id": 132521692,
      "image": "",
      "related": "BMY",
      "source": "DowJones",
      "summary": "Top Dividend Stocks Yielding As High As 5%: Fidelity",
      "url": "https://finnhub.io/api/news?id=b0d5315e4d5c12507ecf204667f73122509f5d6223198730d54f50c14f946dc2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: EU recommends treatment",
    "summary": "Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Breyanzi® , for Breyanzi CAR-T cell therapy...",
    "url": "https://finnhub.io/api/news?id=9b5e4e3cb66dd787c6a189f41b2188e82c0afccb4ae785782eb9634889c58fcb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738313782,
      "headline": "Bristol Myers: EU recommends treatment",
      "id": 132504796,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Breyanzi® , for Breyanzi CAR-T cell therapy...",
      "url": "https://finnhub.io/api/news?id=9b5e4e3cb66dd787c6a189f41b2188e82c0afccb4ae785782eb9634889c58fcb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses",
    "summary": "By Colin Kellaher Bristol Myers Squibb said a key European regulatory committee is backing expanded approvals for its CAR-T cell therapy Breyanzi and its Opdivo plus Yervoy cancer-drug...",
    "url": "https://finnhub.io/api/news?id=784876b4d484254ede1cd83f4a26a6e59e4e49797e4277519af0f2773af4e89c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738310898,
      "headline": "Bristol Myers Gets CHMP Backing for Expanded Breyanzi, Opdivo/Yervoy Uses",
      "id": 132504584,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb said a key European regulatory committee is backing expanded approvals for its CAR-T cell therapy Breyanzi and its Opdivo plus Yervoy cancer-drug...",
      "url": "https://finnhub.io/api/news?id=784876b4d484254ede1cd83f4a26a6e59e4e49797e4277519af0f2773af4e89c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
    "summary": "Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy...",
    "url": "https://finnhub.io/api/news?id=321f805154ac64dafd1a5cdb78c01beb00d60905fdca86b8c0ef64709927276c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738306803,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
      "id": 132504160,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Recommendation based on results of Phase 3 CheckMate -9DW clinical trial demonstrating statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy...",
      "url": "https://finnhub.io/api/news?id=321f805154ac64dafd1a5cdb78c01beb00d60905fdca86b8c0ef64709927276c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
    "summary": "Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete responseAcross clinical trials, Breyanzi has...",
    "url": "https://finnhub.io/api/news?id=e2ffbb457f30807a908fe850cacde80ada18230e1e1a5b7fafe4afb873ada0dc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738306263,
      "headline": "Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma",
      "id": 132504115,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete responseAcross clinical trials, Breyanzi has...",
      "url": "https://finnhub.io/api/news?id=e2ffbb457f30807a908fe850cacde80ada18230e1e1a5b7fafe4afb873ada0dc"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain",
    "summary": "Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly immunotherapy, but it is burdened by a lot of debt. Read more here.",
    "url": "https://finnhub.io/api/news?id=4b1d9f7106db0b1cf9a5dadfab8c9bf6248c64b0bd29f497aae626fda6bf2ad0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738306066,
      "headline": "Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain",
      "id": 132504207,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly immunotherapy, but it is burdened by a lot of debt. Read more here.",
      "url": "https://finnhub.io/api/news?id=4b1d9f7106db0b1cf9a5dadfab8c9bf6248c64b0bd29f497aae626fda6bf2ad0"
    }
  }
]